Search

Metabolic syndrome is one of the most frequent diseases with the augmentation of the rapid changes in societies' lifestyles. On the other hand, various medicinal plants have recently been extensively used for plentiful therapeutics. Among these, curcumin and turmeric are the main components derived from the rhizome of plants, with significant effects on preventing metabolic syndromes. Due to their antioxidant and anti-inflammatory activities, the biological activities of turmeric and its bioactive element, curcumin, have antidiabetic properties via augmenting insulin release and anti-hyperlipidemia effects via enhancing fatty acids uptake, anti-obesity properties via declining lipogenesis, and antihypertensive properties via augmenting nitric oxide synthesis. Moreover, the dietary presence of turmeric and its bioactive element, curcumin, significantly affected poultry productivity, health and welfare. According to human and animal trials, turmeric or curcumin has important values as dietary supplementation and complementary therapy in some metabolic syndromes. This scenario highlights on the potential effects of curcumin (turmeric) on poultry health and its role in complementary therapy in metabolic syndrome. Additional high-quality clinical trial investigations are required to establish the clinical efficiency of the curcumin complement confidently. [ABSTRACT FROM AUTHOR]

Bariatric surgery (BS) has been demonstrated to achieve sustained weight loss with significant metabolic improvement, including a reduction in cardiovascular disease and diabetes. The aim of this retrospective study is to measure the effect of BS on the Framingham risk score (FRS) and metabolic syndrome (MetS) among patients who underwent bariatric surgery. Additionally, we determine the effect of BS on thyroid-stimulating hormone (TSH) among euthyroid obese patients. A retrospective follow-up study was conducted at King Abdullah Medical City, Makkah, Saudi Arabia. A total of 160 patients underwent BS and completed one-year follow-up visits. Medical history, anthropometric, biochemical, and hormonal parameters were evaluated at baseline and 3–12 months after BS. The International Diabetes Federation (IDF) criteria were used to diagnose MetS. There was a significant decrease in systolic blood pressure (SBP), diastolic blood pressure (DBP), glycated hemoglobin (Hba1c), TSH, low-density lipoprotein (LDL), triglycerides, and total cholesterol (p < 0.001). A significant decrease was seen in MetS, BMI, FRS, SBP, DBP, Hba1c, LDL, triglycerides, cholesterol, and liver enzymes, with a significant increase in high-density lipoprotein levels 12 months postoperatively (p < 0.001). At 12 months, the prevalence of MetS, DM, and HTN and the FRS significantly decreased from 72.5%, 43.1%, 78.1%, and 11.4 to 16.3%, 9.4%, 22.5%, and 5.4, respectively. In addition to achieving substantial weight loss, BS improves MetS prevalence and cardiovascular risk profiles. [ABSTRACT FROM AUTHOR]